XENIOS AG, a technology and therapy leader in lung and heart assist, is now part of Fresenius Medical Care & Co. KGaA, Germany’s largest medical device company.
“XENIOS AG will continue to manufacture and market their lung and heart assist product portfolio,” says Dr. Böhm, Co-CEO of XENIOS AG. “Our strategy remains in place, and the processes and contacts remain unchanged. XENIOS AG will continue to serve their customers with the clinical support team and information on XENIOS Campus to advance minimally invasive lung and heart assist therapies.”
XENIOS AG’s Novalung product range for lung assist is a perfect match with renal dialysis.
“This acquisition is a unique opportunity for Fresenius Medical Care to add to their acute renal replacement offerings. Fresenius Medical Care enables us to establish our innovative therapies worldwide, and together we will offer an unrivalled product range for organ assist,” says Dr. Georg Matheis, Co-CEO of XENIOS AG.
The integration of XENIOS and Fresenius Medical Care is a sound basis to establish worldwide market leadership from renal to lung and heart assist. XENIOS’ ongoing R&D projects, including a wearable artificial lung, will be continued.
The closing of the transaction is subject to approval by the authorities.